First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

BACKGROUND: Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients. METHODS: TOPICAL was a double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Siow Ming, Khan, Iftekhar, Upadhyay, Sunil, Lewanski, Conrad, Falk, Stephen, Skailes, Geraldine, Marshall, Ernie, Woll, Penella J, Hatton, Matthew, Lal, Rohit, Jones, Richard, Toy, Elizabeth, Chao, David, Middleton, Gary, Bulley, Sue, Ngai, Yenting, Rudd, Robin, Hackshaw, Allan, Boshoff, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488187/
https://www.ncbi.nlm.nih.gov/pubmed/23078958
http://dx.doi.org/10.1016/S1470-2045(12)70412-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488187/
https://www.ncbi.nlm.nih.gov/pubmed/23078958
http://dx.doi.org/10.1016/S1470-2045(12)70412-6

Ejemplares similares